Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 627 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cirrhosis, Liver Clear all

Conditions: Nonalcoholic Steatohepatitis
Interventions: SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 81
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more

Conditions: Primary Biliary Cirrhosis
Interventions: LUM001; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 10 more

Conditions: Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions: Values Inventory (VI); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: Up to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2029
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Primary Biliary Cirrhosis
Interventions: Clinic visit, Baseline visit; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Primary Biliary Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Liver Cirrhosis
Interventions: Dynamic Contrast-Enhanced Ultrasound Imaging; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: San Diego, California • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more

Conditions: Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions: ESG + lifestyle modification, Lifestyle modification; Device · Behavioral
Lead sponsor: Pichamol Jirapinyo, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • Morgantown, West Virginia

Conditions: Liver Cirrhosis, Sarcopenia
Interventions: LPCN 1148, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions: VS-01 on top of SOC (Active Treatment Group), SOC; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Cirrhosis, Diabetes Mellitus, Type 2
Interventions: Continuous glucose monitor (Dexcom, San Diego, CA); Device
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions: skin punch biopsy collection, Blood collection, Urine sample collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Liver Fibroses
Interventions: Ultrasound with ARFI (acoustic radiation force impulse), Ultrasound with backscatter imaging; Device
Lead sponsor: University of Michigan; Other
Eligibility: 2 Years to 5 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Clinically Significant Portal Hypertension
Interventions: Placebo, Sorafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 20 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 6
States / cities: New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: solithromycin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cirrhosis, Liver Failure
Interventions: Empagliflozin 10 MG, Matching Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alcoholic Cirrhosis
Interventions: Placebo, SAMe 400 mg tablet; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Indianapolis, Indiana

Conditions: Hepatorenal Syndrome, Renal Failure, Liver Diseases
Interventions: Blood Draws and a hepatectomy specimen, Blood draw - pre operative standard of care; Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions: Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions: Rosuvastatin; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 7 more

Conditions: Liver Fibrosis, Hepatic Cirrhosis
Interventions: AZD2389; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Chandler, Arizona • Rialto, California • Atlanta, Georgia + 3 more

Conditions: Cirrhosis of the Liver, Ascites, Spontaneous Bacterial Peritonitis
Interventions: Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin); Other
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Liver Transplant, Hepatitis C
Interventions: Cyclosporine A, Tacrolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Liver Cancer
Interventions: Magnetic Resonance Elastogram, 2-Point Dixon Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

Longitudinal Study of Mitochondrial Hepatopathies

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

Bartonella in Liver Transplant Patients

Increased Liver Stiffness: A Study of Acoustic Radiation Force Impulse (ARFI) Elastography

The Effect of Sorafenib on Portal Pressure

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

Empagliflozin in Patients With Cirrhosis and Ascites

SAMe Trial for Patients With Alcoholic Cirrhosis

Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease